Not currently recruiting at UCLA

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

a study on Elevated Lp(a) Cardiovascular Disease Atherosclerosis Peripheral Artery Disease

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Torrance, California and other locations
Dates
study started
study ends around
Principal Investigator
by Dianne Cheung

Description

Summary

The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.

Official Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event

Keywords

Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD), Atherosclerosis, Muvalaplin

Eligibility

You can join if…

Open to people ages 18 years and up

  • Have Lp(a) ≥175 nanomoles per liter (nmol/L)
  • Meet one of the following criteria:
    • Have had a prior atherosclerotic cardiovascular disease (ASCVD) event (such as heart attack, stroke, or procedure to restore blood flow to the heart or other parts of the body) within 10 years prior to screening
    • Are at risk for a first ASCVD event, defined as one or more of the following:
      • Documented coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without a history of ASCVD event
      • A high coronary artery calcium (CAC) score
      • Reduced kidney function with diabetes
      • Combination(s) of high risk factors

You CAN'T join if...

  • Have experienced a major cardiovascular event or surgery, such as heart attack, stroke, or procedure to restore blood flow to the heart or other parts of the body, within 90 days prior to screening or occurring between screening and randomization
  • Are planning or expected to undergo a procedure to restore blood flow in the arteries or a major heart surgery during the study
  • Have uncontrolled high blood pressure
  • Have New York Heart Association (NYHA) class III or IV heart failure
  • Have undergone a procedure to remove cholesterol from the blood within 90 days of screening, or have a planned procedure during the study
  • Have severe kidney impairment
  • Have had cancer within 5 years prior to screening

Locations

  • UCLA South Bay Endocrinology not yet accepting patients
    Torrance California 90505 United States
  • Ark Clinical Research - Fountain Valley accepting new patients
    Fountain Valley California 92708 United States
  • Clinical Research of South Nevada accepting new patients
    Las Vegas Nevada 89121 United States

Lead Scientist at UCLA

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) )
ID
NCT07157774
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 10450 study participants
Last Updated